Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
Intermittent hypoxia (IH) is associated with increased endothelial dysfunction and cardiovascular disorders. Exosomes released in biological fluids may act as vehicles for propagating such damage, modifying the functional phenotype of endothelial cells. Drug interventions, however, may provide prote...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00709/full |
id |
doaj-d1178464d20b4ec8974dc03120cc2cd1 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdelnaby Khalyfa Nina Youssefnia Glen E. Foster Glen E. Foster Andrew E. Beaudin Andrew E. Beaudin Zhuanghong Qiao Vincent Pialoux Vincent Pialoux Matiram Pun Matiram Pun Patrick J. Hanly Patrick J. Hanly Leila Kheirandish-Gozal Marc J. Poulin Marc J. Poulin Marc J. Poulin Marc J. Poulin Marc J. Poulin David Gozal |
spellingShingle |
Abdelnaby Khalyfa Nina Youssefnia Glen E. Foster Glen E. Foster Andrew E. Beaudin Andrew E. Beaudin Zhuanghong Qiao Vincent Pialoux Vincent Pialoux Matiram Pun Matiram Pun Patrick J. Hanly Patrick J. Hanly Leila Kheirandish-Gozal Marc J. Poulin Marc J. Poulin Marc J. Poulin Marc J. Poulin Marc J. Poulin David Gozal Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia Frontiers in Neurology cardiovascular disease intermittent hypoxia sleep apnea experimental human model endothelium exosomes |
author_facet |
Abdelnaby Khalyfa Nina Youssefnia Glen E. Foster Glen E. Foster Andrew E. Beaudin Andrew E. Beaudin Zhuanghong Qiao Vincent Pialoux Vincent Pialoux Matiram Pun Matiram Pun Patrick J. Hanly Patrick J. Hanly Leila Kheirandish-Gozal Marc J. Poulin Marc J. Poulin Marc J. Poulin Marc J. Poulin Marc J. Poulin David Gozal |
author_sort |
Abdelnaby Khalyfa |
title |
Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia |
title_short |
Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia |
title_full |
Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia |
title_fullStr |
Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia |
title_full_unstemmed |
Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia |
title_sort |
plasma exosomes and improvements in endothelial function by angiotensin 2 type 1 receptor or cyclooxygenase 2 blockade following intermittent hypoxia |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2017-12-01 |
description |
Intermittent hypoxia (IH) is associated with increased endothelial dysfunction and cardiovascular disorders. Exosomes released in biological fluids may act as vehicles for propagating such damage, modifying the functional phenotype of endothelial cells. Drug interventions, however, may provide protection for the endothelium, in spite of exosomal activity. Using an experimental human model of IH, we investigated whether the beneficial effects of two drugs, celecoxib (CEL) and losartan (LOS), on IH-induced vascular dysfunction was mediated via exosomes or independent of IH-induced exosomal cargo alterations. We hypothesized that the beneficial effects of CEL and LOS on IH-induced vascular dysfunction would be mediated via modifications of exosomal properties by the drugs, rather than by direct effects of the drugs on the endothelium. Ten male volunteers were exposed to IH (single exposure of 6 h) while receiving LOS, CEL, or placebo (P) for 4 days before IH exposures, and plasma samples were obtained from which exosomes were isolated, and incubated with naïve human endothelial cell cultures either not treated or pretreated with LOS, CEL, or P. Functional reporter assays (monolayer impedance, monocyte adhesion, and eNOS phosphorylation) revealed that the degree of exosome-induced endothelial dysfunction was similar among IH-exposed subjects independent of drug treatment. However, pretreatment of naïve endothelial cells with LOS or CEL before addition of exosomes from IH-exposed subjects afforded significant protection. Thus, the cardiovascular protective impact of LOS and CEL appears to be mediated by their direct effects on endothelial cells, rather than via modulation of exosomal cargo. |
topic |
cardiovascular disease intermittent hypoxia sleep apnea experimental human model endothelium exosomes |
url |
http://journal.frontiersin.org/article/10.3389/fneur.2017.00709/full |
work_keys_str_mv |
AT abdelnabykhalyfa plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT ninayoussefnia plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT glenefoster plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT glenefoster plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT andrewebeaudin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT andrewebeaudin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT zhuanghongqiao plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT vincentpialoux plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT vincentpialoux plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT matirampun plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT matirampun plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT patrickjhanly plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT patrickjhanly plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT leilakheirandishgozal plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia AT davidgozal plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia |
_version_ |
1725705138442600448 |
spelling |
doaj-d1178464d20b4ec8974dc03120cc2cd12020-11-24T22:40:16ZengFrontiers Media S.A.Frontiers in Neurology1664-22952017-12-01810.3389/fneur.2017.00709324689Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent HypoxiaAbdelnaby Khalyfa0Nina Youssefnia1Glen E. Foster2Glen E. Foster3Andrew E. Beaudin4Andrew E. Beaudin5Zhuanghong Qiao6Vincent Pialoux7Vincent Pialoux8Matiram Pun9Matiram Pun10Patrick J. Hanly11Patrick J. Hanly12Leila Kheirandish-Gozal13Marc J. Poulin14Marc J. Poulin15Marc J. Poulin16Marc J. Poulin17Marc J. Poulin18David Gozal19Section of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, CanadaFaculty of Kinesiology, University of Calgary, Calgary, AB, CanadaSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesIntermittent hypoxia (IH) is associated with increased endothelial dysfunction and cardiovascular disorders. Exosomes released in biological fluids may act as vehicles for propagating such damage, modifying the functional phenotype of endothelial cells. Drug interventions, however, may provide protection for the endothelium, in spite of exosomal activity. Using an experimental human model of IH, we investigated whether the beneficial effects of two drugs, celecoxib (CEL) and losartan (LOS), on IH-induced vascular dysfunction was mediated via exosomes or independent of IH-induced exosomal cargo alterations. We hypothesized that the beneficial effects of CEL and LOS on IH-induced vascular dysfunction would be mediated via modifications of exosomal properties by the drugs, rather than by direct effects of the drugs on the endothelium. Ten male volunteers were exposed to IH (single exposure of 6 h) while receiving LOS, CEL, or placebo (P) for 4 days before IH exposures, and plasma samples were obtained from which exosomes were isolated, and incubated with naïve human endothelial cell cultures either not treated or pretreated with LOS, CEL, or P. Functional reporter assays (monolayer impedance, monocyte adhesion, and eNOS phosphorylation) revealed that the degree of exosome-induced endothelial dysfunction was similar among IH-exposed subjects independent of drug treatment. However, pretreatment of naïve endothelial cells with LOS or CEL before addition of exosomes from IH-exposed subjects afforded significant protection. Thus, the cardiovascular protective impact of LOS and CEL appears to be mediated by their direct effects on endothelial cells, rather than via modulation of exosomal cargo.http://journal.frontiersin.org/article/10.3389/fneur.2017.00709/fullcardiovascular diseaseintermittent hypoxiasleep apneaexperimental human modelendotheliumexosomes |